MNPR Company Profile and Key Details

Q: Who are the executives of MNPR?

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MScCo-Founder, Chief Executive Officer, Pres & DirectorMs. Kim R. Tsuchimoto CPAChief Financial Officer, Sec., Treasurer & DirectorMr. Andrew J. Cittadine M.B.A.Chief Operating OfficerDr. Patrice P. Rioux M.D., Ph.D.Acting Chief Medical Officer

NASDAQ : MNPR

Monopar Therapeutics

$108.32

-1.94-1.76%

At Close 4:00 PM

64.5

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Monopar Therapeutics Inc. (MNPR) stock declined over -3.68%, trading at $104.33 on NASDAQ, down from the previous close of $108.32. The stock opened at $105.81, fluctuating between $101.86 and $105.84 in the recent session.

Stock Snapshot

108.32

Prev. Close

698.91M

Market Cap

101.855

Day Low

-48.08

P/E Ratio

-2.17

EPS (TTM)

-0.53

Cash Flow per Share

105.81

Open

6.7M

Number of Shares

105.84

Day High

64.1%

Free Float in %

0.37

Book Value

87.74K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 14, 2026	111.99	111.99	107.02	108.32	106.57K
Sep 11, 2026	113.84	113.84	109.77	110.26	90.05K
Sep 10, 2026	110.55	112.56	108.84	109.96	89.54K
Sep 09, 2026	112.31	116.61	112.19	112.38	110.27K
Sep 08, 2026	115.61	117.61	113.27	114.38	91.34K
Sep 04, 2026	117.85	119.00	116.21	117.56	81.4K
Sep 03, 2026	117.44	121.02	115.07	118.55	208.05K
Sep 02, 2026	119.04	121.00	114.28	116.28	203.35K
Sep 01, 2026	110.21	118.00	110.21	117.57	95.17K
Aug 31, 2026	110.70	112.97	106.67	111.93	140.75K
Aug 28, 2026	112.85	113.99	109.14	111.89	221.54K
Aug 27, 2026	113.80	117.50	112.45	113.94	142.83K
Aug 26, 2026	111.26	114.75	108.22	113.72	123.77K
Aug 25, 2026	113.11	114.79	108.84	110.82	133.19K
Aug 24, 2026	106.99	113.47	104.48	111.36	239.18K
Aug 21, 2026	111.98	113.46	105.42	107.72	176.42K
Aug 20, 2026	122.01	122.60	110.84	110.88	208.1K
Aug 19, 2026	118.50	124.27	114.81	123.84	400.34K
Aug 18, 2026	115.00	120.00	113.79	119.05	143.38K
Aug 17, 2026	113.35	117.00	111.60	116.49	171.11K

Contact Details

Wilmette, IL 60091

United States

https://www.monopartx.com 847 388 0349

About Company

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Stock Peers

ARGX

6.15+0.62%

argenx SE$990.54 REGN

12.25+1.57%

Regeneron Pharmaceuticals, Inc.$793.74 MDGL

5.57+1.04%

Madrigal Pharmaceuticals, Inc.$540.06 VRTX

4.07+0.79%

Vertex Pharmaceuticals Incorporated$519.51 UTHR

5.59+1.12%

United Therapeutics Corporation$502.70 ONC

7.32+2.11%

BeOne Medicines AG$353.83 KRYS

-6.97-2.01%

Krystal Biotech, Inc.$340.03 PRAX

-4.03-1.20%

Praxis Precision Medicines, Inc.$330.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

-3.82-1.34%

Ligand Pharmaceuticals Incorporated$280.65

Frequently Asked Questions

What is the current Monopar Therapeutics Inc. (MNPR) stock price?

Monopar Therapeutics Inc. (NASDAQ: MNPR) stock price is $104.33 in the last trading session. During the trading session, MNPR stock reached the peak price of $105.84 while $101.86 was the lowest point it dropped to. The percentage change in MNPR stock occurred in the recent session was -3.68% while the dollar amount for the price change in MNPR stock was - $3.99.

MNPR's industry and sector of operation?

The NASDAQ listed MNPR is part of Biotechnology industry that operates in the broader Healthcare sector. Monopar Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MNPR?

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Co-Founder, Chief Executive Officer, Pres & Director
Ms. Kim R. Tsuchimoto CPA
Chief Financial Officer, Sec., Treasurer & Director
Mr. Andrew J. Cittadine M.B.A.
Chief Operating Officer
Dr. Patrice P. Rioux M.D., Ph.D.
Acting Chief Medical Officer

How MNPR did perform over past 52-week?

MNPR's closing price is 131.01% higher than its 52-week low of $50.07 where as its distance from 52-week high of $124.82 is -13.22%.

How many employees does MNPR have?

Number of MNPR employees currently stands at 22.

Link for MNPR official website?

Official Website of MNPR is: https://www.monopartx.com

How do I contact MNPR?

MNPR could be contacted at phone 847 388 0349 and can also be accessed through its website. MNPR operates from 1000 Skokie Boulevard, Wilmette, IL 60091, United States.

How many shares of MNPR are traded daily?

MNPR stock volume for the day was 87.74K shares. The average number of MNPR shares traded daily for last 3 months was 219.79K.

What is the market cap of MNPR currently?

The market value of MNPR currently stands at $698.91M with its latest stock price at $104.33 and 6.7M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	22
Beta	1.5
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	22
Beta	1.5
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MNPR Company Profile and Key Details

Monopar Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways